Kalaris Therapeutics, Inc. (KLRS) Dividend History

Kalaris Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company leverages its proprietary platform to discover and advance treatments aimed at modulating the immune system to restore balance and improve patient outcomes.

Dividend History

Kalaris Therapeutics, Inc. currently does not pay dividends

Company News

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics reported Q2 2025 financial results, continuing enrollment in a Phase 1 trial for TH103, a novel anti-VEGF treatment for retinal diseases. The company has $88.4M in cash, expects initial clinical data in Q4 2025, and reported a net loss of $11.4 million for the quarter.

GlobeNewswire Inc.

Page data last updated 08/19/2025 16:43:47 UTC